Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14721160 | 1.00 | ESR1 (0.42) | ESR1APPGLSABCB1AAK1 | |
| SCHEMBL7746373 | 0.84 | GABRA1 (0.47) | APPAAK1ITGA4ITGB7LMNA | |
| SCHEMBL16410353 | 0.83 | APP (0.37) | APPABCB1AAK1LMNAKMT2A | |
| SCHEMBL16811751 | 0.83 | ITGA4 (0.47) | GLSITGA4ITGB7LMNAKMT2A | |
| SCHEMBL29348332 | 0.80 | HTT (0.37) | APPAAK1LMNAKMT2AMAPK1 | |
| SCHEMBL16782681 | 0.80 | MEN1 (0.46) | LMNAKMT2AALDH1A1ADRB2ADRB1 | |
| SCHEMBL5216247 | 0.80 | ITGA4 (0.40) | APPABCB1AAK1ITGA4ITGB7 | |
| SCHEMBL29348334 | 0.80 | APP (0.36) | APPAAK1LMNAKMT2AL3MBTL1 | |
| SCHEMBL16782680 | 0.80 | MEN1 (0.46) | LMNAKMT2AALDH1A1ADRB2ADRB1 | |
| SCHEMBL6017451 | 0.79 | KMT2A (0.47) | ESR1GLSACP3KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276732-B1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | DOMPE PHA R MA SPA RES & MFG (IT) | 2007-09-26 | — | — | EP | disclosed |
| US-7217707-B2 | Amide of R-2-(aminoaryl)-propionic acid for use in the prevention of leucocyte activation | DOMPE S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-23 | — | — | US | disclosed |
| EP-1276732-A1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | Dompé S.P.A. (IT) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079189-A2 | 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' | Dompé S.p.A. (IT) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | MMP8, CXCL8, HCAR2 | ESR1 4416/4885APP 2281/4885GLS 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.